{"id":"NCT02345252","sponsor":"Gilead Sciences","briefTitle":"Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)","officialTitle":"A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-26","primaryCompletion":"2016-06-22","completion":"2019-01-09","firstPosted":"2015-01-26","resultsPosted":"2017-12-08","lastUpdate":"2020-01-02"},"enrollment":632,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"FTC/RPV/TAF","otherNames":["Odefsey®"]},{"type":"DRUG","name":"FTC/RPV/TDF Placebo","otherNames":[]},{"type":"DRUG","name":"FTC/RPV/TDF","otherNames":["Complera®","Eviplera®"]},{"type":"DRUG","name":"FTC/RPV/TAF Placebo","otherNames":[]}],"arms":[{"label":"FTC/RPV/TAF","type":"EXPERIMENTAL"},{"label":"FTC/RPV/TDF","type":"ACTIVE_COMPARATOR"},{"label":"Open Label Extension Phase","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the noninferiority of switching to emtricitabine/rilpivirine /tenofovir alafenamide (FTC/RPV/TAF) fixed-dose combination (FDC) as compared to continuing FTC/RPV/tenofovir disoproxil fumarate (TDF) FDC (FTC/RPV/TDF) in virologically suppressed HIV-1 infected participants.","primaryOutcome":{"measure":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm","timeFrame":"Week 48","effectByArm":[{"arm":"FTC/RPV/TAF","deltaMin":93.7,"sd":null},{"arm":"FTC/RPV/TDF","deltaMin":93.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"1.00"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":11},"locations":{"siteCount":117,"countries":["United States","Belgium","Canada","France","Germany","Italy","Netherlands","Puerto Rico","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["30101539","28259777"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":316},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Back pain","Arthralgia"]}}